In placebo-controlled phase III studies of gefitinib (Thatcher et al, 2005) and erlotinib (Shepherd et al, 2005; Cappuzzo et al, 2010a), patients with EGFR-mutated tumours had significantly higher RR compared with patients with wild-type tumours. This evidence concerns the gene EGFR and neoplasm.